The U.S. Food and Drug Administration has granted Breakthrough Device Designation to two generative AI radiology tools aimed at accelerating chest X-ray interpretation and streamlining report creation. The designation, part of the FDA Breakthrough Devices Program, is designed to speed development and regulatory interaction for technologies that may offer more effective diagnosis for life-threatening or irreversibly debilitating conditions.

While the designation is not the same as clearance or approval, it can provide more structured engagement with FDA experts and prioritized review pathways. The announcements also land amid broader FDA work on how to evaluate next-generation AI in medicine, including current thinking outlined in its discussion paper on regulating GenAI-enabled medical devices.

What the designated products are designed to do

One designation went to Mosaic Clinical Technologies’ Cognita Chest X-Ray (CXR), described by the company as a generative vision-language model intended to assist radiologists in interpreting chest radiographs and producing preliminary findings across multiple critical indications.

The second designation was awarded to Aidoc for First Read, a GenAI tool designed to analyze chest radiographs and generate draft radiology report text; Aidoc said the designation covers use for four life-threatening findings and emphasized ongoing clinician oversight in final sign-off.

Radiology is entering a new era.

Why it matters for workflow, safety, and oversight

Developers argue that report-drafting GenAI could help radiology teams manage growing imaging demand while keeping radiologists responsible for medical judgment. The FDA has also noted that Breakthrough designation is voluntary and generally isn’t publicly disclosed by the agency unless a sponsor chooses to share it.

In Finland, interest in trustworthy clinical AI is also rising, as Fimea’s medical devices guidance underscores manufacturer responsibilities and post-market vigilance, and professional discussions increasingly reference quality and safety expectations tied to national care oversight such as Valvira’s healthcare supervision.